Lombard Odier Asset Management Europe Ltd Has $13.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Lombard Odier Asset Management Europe Ltd reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,875 shares of the biopharmaceutical company’s stock after selling 3,124 shares during the period. Lombard Odier Asset Management Europe Ltd’s holdings in Regeneron Pharmaceuticals were worth $13,811,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. WPG Advisers LLC lifted its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $29,000. Finally, Kemnay Advisory Services Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results
• Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates
• Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst.
• Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action

Wall Street Analyst Weigh In

REGN has been the topic of several recent analyst reports. HSBC dropped their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Truist Financial upped their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday. Finally, JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $794.83.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $762.63 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $643.13 and its 200 day moving average is $711.31. The stock has a market capitalization of $80.63 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 28.06 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.81 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 2.06 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.